Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline ...
Boehringer Ingelheim (BI) has announced positive top-line results from a late-stage study of its investigational ...
The two positive studies mean that Boehringer can now seek approval for nerandomilast with a broad label claim in pulmonary ...
The "Cough in Idiopathic Pulmonary Fibrosis (IPF) - Epidemiology Forecast - 2034" report has been added tAndMarkets.com's offering.The report delivers an in-depth understanding of the Cough in ...
Boehringer Ingelheim’s FIBRONEER-ILD phase III study of nerandomilast to treat progressive pulmonary fibrosis meets primary endpoint: Ingelheim, Germany Wednesday, February 12, ...
Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...
Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...
Did you see this? Nearly 1 in 10 Americans have asthma. Here's what causes it.
Low total cholesterol levels were tied to an increased risk of death for pulmonary fibrosis patients with disease of unknown ...
Researchers have been trying for decades to stop the cells that damage the lung in people with pulmonary fibrosis. Now a team ...
Topline data from FIBRONEERâ„¢-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback